- Health Canada has approved Apo-Semaglutide Injection by Apotex, making it the first Canadian-based company authorized for a generic equivalent of Ozempic (semaglutide)
- The once-weekly GLP-1 therapy is indicated for adults with type 2 diabetes to improve glycemic control alongside diet and exercise and will be available in both 2 mg and 4 mg pen formats
- Developed in partnership with Orbicular Pharmaceutical Technologies, the product completed Health Canada’s regulatory review process for peptide medicines
- The approval expands access to more affordable semaglutide options in Canada, reinforcing Apotex’s focus on high-quality generics and healthcare system sustainability
Takeaways
Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and employer plans that prioritize lower‑cost options.
Because Apotex is the first Canadian company with a generic and can match the key 2 mg and 4 mg pen formats, it is well placed to win share via tenders and formulary listings, while also nudging broader GLP‑1 access by making semaglutide more affordable for type 2 diabetes—and indirectly supporting continued off‑label weight‑management use where payers allow it.
Source: Apotex
